ClinicalTrials.gg
CompletedNCT03914534Updated Apr 16, 2019

Bioequivalence Study of Sodium Divalproate Tablets 500 mg

A Phase 4 interventional study of Valproic Acid 500 MG and Valcote 500 mg in Healthy, sponsored by Tecnoquimicas. Completed at 1 site in Colombia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Tecnoquimicas · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2017, registered Apr 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objective of this study is to establish the bioequivalence of two valproic acid formulations through the estimation of valproic acid in plasma samples, according to Food and Drugs Administration (FDA), World Health Organization (WHO) and Colombian National Vigilance Institute for Drugs and Food (INVIMA) guidelines.

Read the detailed description

This will be a single-center, open-label, four-period, two-treatment, two-sequence, randomized, single-dose, crossover study. 30 healthy adults will be randomized to receive a single dose (500 mg) of the test formulation of valproic acid and reference formulation of valproic acid separately in each treatment period. There will be two treatment sequences (AB, BA) and a 7 day washout between the two treatment periods.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tecnoquimicas is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and Women from 18 to 50 years old
  • Diagnosed as healthy after a clinical examination
  • from 18 to 30 kg/m2
  • Not smoking for at least 3 months
  • To sign the
  • Not having participated in a similar study for at least 4 months

Exclusion criteria

Exclusion Criteria:

  • Renal, cardiac immunological, dermatological, endocrine, gastrointestinal, neurological or psychiatric condition
  • Hematologic disorders, specially anemia and polycythemia
  • Permanent or temporal pharmacological therapy, prescribed or not
  • Smoking for the last 3 months
  • Alcohol drinker more than once a week
  • Drug abuse
  • Drug
  • Angioedema or anaphylaxis history
  • Pregnancy or breast-feeding
  • o diagnosed
  • Blood donor in the past 30 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Test Formulation of Valproic Acid

    Valproic Acid tablets 500 mg Single dose administered in dosing period 1 or 2

    Drug: Valproic Acid 500 MG

  • Active comparator
    Reference Formulation of Valproic Acid

    Valcote tablets 500 mg Single dose administered in dosing period 1 or 2

    Drug: Valcote 500 mg

Interventions

  • Administration of 500 mg of Valproic Acid

  • DrugValcote 500 mg

    Administration of 500 mg of Valproic Acid

06

What researchers measure

Primary outcomes

  1. (AUC) Area Under the Curve 0-48

    0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours

    Time frame: From 0 to 48 hours

  2. Cmax

    0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours

    Time frame: From 0 to 48 hours

Secondary outcomes

  1. Tmax

    0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours

    Time frame: From 0 to 48 hours

  2. Kel

    0, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 y 48 hours

    Time frame: From 0 to 48 hours

07

Study locations

1 site
  • Universidad de la Sabana
    Chía, Colombia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Jul 2018, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2019
First posted
Apr 16, 2019
StartActual
Apr 17, 2017
Primary completionActual
Jul 31, 2018
CompletionActual
Feb 12, 2019
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03914534
Lead sponsor
Tecnoquimicas
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Apr 17, 2017
Primary completion
Jul 31, 2018
Completion
Feb 12, 2019
Last update
Apr 16, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion